Skip to content

Miguel Angel Herrera Rojas

  • Janssen Pharmaceuticals Inc
  • 3h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 31CitationsNumber of citations received by Miguel Angel's publications. Updated daily.

Other IDs

Co-authors (69)

Publications (5)

  • Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure.

    • Gómez-Almaguer D, Saldaña-Vázquez R, Tarín-Arzaga L, Herrera-Rojas MA, de Larracoechea VM, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH J
    N/AReaders
    N/ACitations
  • Long-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell Transplant.

    • Cantú-Rodríguez OG, Lavalle-González F, Herrera-Rojas MÁ, Jaime-Pérez JC, Hawing-Zárate JÁ, Homero Gutiérrez-Aguirre C, Mancias-Guerra C, González-Llano O, Zapata-Garrido A, Zacarias Villarreal-Pérez J G
    N/AReaders
    N/ACitations
  • No clinically relevant differences between capillary and venous blood cell counts in adult haematological patients using a nonautomated lancet

    • Herrera-Rojas M
    • Tarín-Arzaga L
    • Gómez-De León A
    • et al.
    N/AReaders
    0Citations
    Get full text
  • Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience

    • Schcolnik-Cabrera A
    • Labastida-Mercado N
    • Labastida-Mercado N
    • et al.
    N/AReaders
    1Citations
    Get full text
  • Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

    • Gómez-Almaguer D
    • Herrera-Rojas M
    • Jaime-Pérez J
    • et al.
    N/AReaders
    21Citations
    Get full text

Professional experience

Janssen Pharmaceuticals Inc